Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncologist. 2010;15(10):1026-33. doi: 10.1634/theoncologist.2010-0087. Epub 2010 Oct 7.

Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.

Author information

  • 1University of Oklahoma Health Sciences Center, 4502 East 41st Street, Tulsa, Oklahoma 74135, USA.

Abstract

Adenocarcinoma of the endometrium represents the most common gynecologic malignancy in developed countries. Although early-stage cancers are effectively treated surgically, commonly without adjuvant therapy, the treatment of high-risk and advanced disease is more complex. Chemotherapy has evolved into an important modality in high-risk early-stage and advanced-stage disease, and in recurrent endometrial cancer. Taxane-based therapy consistently demonstrates the highest response rates in the first-line and salvage settings of endometrial cancer. Unfortunately, response to chemotherapy is modest and strategies are needed to predict chemotherapy-responsive and chemotherapy-resistant populations. Chemotherapy resistance mediated by overexpression of drug efflux pump proteins and mutations in β-tubulin isoforms in both primary and recurrent disease represent unique treatment challenges and highlight the need for new agents that are less susceptible to these known resistance pathways. Epothilone B analogs are novel cytotoxic agents with activity in solid tumors, including advanced/recurrent endometrial carcinoma, and may have unique properties that can overcome resistance in some settings. These agents alone and in combination represent a new therapeutic opportunity in endometrial carcinoma.

PMID:
20930101
[PubMed - indexed for MEDLINE]
PMCID:
PMC3227900
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk